Suppr超能文献

非手术意向的直肠癌全新辅助治疗的相关结局。

Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma.

作者信息

Asare Ebenezer, Venner Emily, Batchelor Hanna, Sanders Jason, Kunk Paul, Hedrick Traci, Hoang Sook, Reilley Matthew, Le Tri, Friel Charles, Janowski Einsley-Marie

机构信息

Department of Radiation Oncology, University of Virginia, Charlottesville, VA, United States.

University of Virginia School of Medicine, Charlottesville, VA, United States.

出版信息

Front Oncol. 2024 Jul 29;14:1374360. doi: 10.3389/fonc.2024.1374360. eCollection 2024.

Abstract

PURPOSE/OBJECTIVES: To evaluate rates of clinical complete response (cCR), surgery-free survival, permanent ostomy-free survival, and factors associated with these outcomes in patients treated with total neoadjuvant therapy (TNT) with intent for non-operative management of rectal adenocarcinoma.

METHODS

A retrospective review was conducted of patients treated with TNT for stage II-IV rectal adenocarcinoma (n=45) at our institution between 2013 - 2022 with curative intent. All patients received radiation with concurrent capecitabine and additional chemotherapy, either prior to or following chemoradiation (CRT), with intent for non-operative management. Response rates were determined based on post-treatment MRI and endoscopy. Kaplan-Meier method was utilized to estimate the 1- and 2-year surgery- and permanent ostomy-free survivals. Cox regression was used to evaluate associations between surgery- and permanent ostomy-free survivals and various factors of interest, including patient and tumor characteristics and clinical response. Chi-squared analysis compared rates of cCR and surgery by sequence of TNT modality and cell count ratios.

RESULTS

Of the 45 patients treated with TNT, most patients had low-lying rectal tumors with a median distance of 4.1 cm from the anal verge (range, 0.0 - 12.0). Overall, 64.4% (n=29) achieved cCR after TNT. 13 patients (28.9%) underwent surgical resection following TNT, 12 of whom had incomplete response and one who elected to undergo surgery after reaching cCR. At median follow up of 32.0 months (range, 7.1 - 86.1), 22.2% (n=10) of patients had a permanent colostomy, with only 2 of these completed for tumor regrowth after cCR. At one and two years, respectively, surgery-free survival was 77.3% and 66.2%, and permanent ostomy-free survival was 90.9% and 78.2%. Rates of cCR were higher in patients who received CRT first compared to those who received chemotherapy first (72.2% vs. 33.3%, =0.029) and rates of surgery were also lower in patients who received CRT first compared to those who received chemotherapy first (19.4% vs. 66.7%, p=0.005). On Cox regression model, cCR on 6 month post-CRT endoscopy was associated with surgery-free survival (p=0.006) and permanent ostomy-free survival (=0.033). Clinical response at earlier follow up points did not predict surgery- nor permanent ostomy-free survival.

CONCLUSION

These results support evidence that TNT may be a non-surgical option for select patients with rectal adenocarcinoma who desire organ preservation. In this investigation at a single institution, the treatment response on 6-month post-CRT endoscopy was the best predictor of surgery- and permanent ostomy-free survival, which are outcomes that are important to patient quality of life. CRT followed by consolidation chemotherapy was associated with higher rates of cCR and lower rates of surgery compared to those treated with induction chemotherapy.

摘要

目的/目标:评估接受全新辅助治疗(TNT)以非手术方式治疗直肠腺癌患者的临床完全缓解(cCR)率、无手术生存、无永久性造口生存以及与这些结局相关的因素。

方法

对2013年至2022年期间在本机构接受TNT治疗的II-IV期直肠腺癌患者(n = 45)进行回顾性研究,目的是治愈。所有患者在同步放化疗(CRT)之前或之后接受放疗并同时使用卡培他滨及额外化疗,目的是进行非手术治疗。根据治疗后的MRI和内镜检查确定缓解率。采用Kaplan-Meier方法估计1年和2年的无手术生存及无永久性造口生存。使用Cox回归评估无手术生存及无永久性造口生存与各种感兴趣因素之间的关联,包括患者和肿瘤特征以及临床缓解情况。卡方分析比较了TNT治疗方式顺序和细胞计数比例的cCR率和手术率。

结果

在接受TNT治疗的45例患者中,大多数患者患有低位直肠肿瘤,距肛缘的中位距离为4.1厘米(范围0.0 - 12.0厘米)。总体而言,64.4%(n = 29)的患者在TNT治疗后达到cCR。13例患者(28.9%)在TNT治疗后接受了手术切除,其中12例缓解不完全,1例在达到cCR后选择接受手术。在中位随访32.0个月(范围7.1 - 86.1个月)时,22.2%(n = 10)的患者有永久性结肠造口,其中只有2例是由于cCR后肿瘤复发而完成造口。在1年和2年时,无手术生存率分别为77.3%和66.2%,无永久性造口生存率分别为90.9%和78.2%。与先接受化疗的患者相比,先接受CRT的患者cCR率更高(72.2%对33.3%,p = 0.029),且先接受CRT的患者手术率也低于先接受化疗的患者(19.4%对66.7%,p = 0.005)。在Cox回归模型中,CRT后6个月内镜检查时的cCR与无手术生存(p = 0.006)和无永久性造口生存(p = 0.033)相关。早期随访时的临床缓解情况并不能预测无手术生存或无永久性造口生存。

结论

这些结果支持以下证据,即TNT可能是某些希望保留器官的直肠腺癌患者的非手术选择。在本单机构研究中,CRT后6个月内镜检查的治疗反应是无手术生存和无永久性造口生存的最佳预测指标,而这些结局对患者生活质量很重要。与接受诱导化疗的患者相比,CRT后巩固化疗与更高的cCR率和更低的手术率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ca/11328831/e924ba526ac6/fonc-14-1374360-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验